Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 17/20 | 0.42 |
| ▸ | PDE4A | P27815 | 16/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889671 | 1.00 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CTNKS | |
| SCHEMBL2889672 | 1.00 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CTNKS | |
| SCHEMBL5734370 | 0.87 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CTNKS | |
| SCHEMBL2890083 | 0.84 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CTNKS | |
| SCHEMBL5733765 | 0.80 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CMEN1 | |
| SCHEMBL2881474 | 0.77 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2881470 | 0.77 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2881473 | 0.77 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL5972842 | 0.76 | PTPRC (0.49) | PDE4DPDE4APDE4BPDE4CTNKS | |
| SCHEMBL5972846 | 0.76 | PTPRC (0.49) | PDE4DPDE4APDE4BPDE4CTNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045456-B2 | Compositions and methods for treating COPD and other inflammatory conditions | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| CN-112105611-A | Pharmaceutical combination comprising a Histone Deacetylase (HDAC) inhibitor and a TLR7 agonist and/or a TLR8 agonist for the treatment of cancer | 4SC股份公司 | 2020-12-18 | — | — | CN | disclosed |
| US-20180042904-A1 | COMPOSITIONS AND METHODS FOR TREATING COPD AND OTHER INFLAMMATORY CONDITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-7790710-B2 | Imidazopyridine derivatives useful as iNOS inhibitors | NYCOMED GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| US-7776893-B2 | Use of PDE4 inhibitors for the treatment of diabetes mellitus | NYCOMED GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-7714134-B2 | Compounds and use of tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090274676-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A PDE-4 INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS, LLC | 2009-11-05 | — | — | US | disclosed |
| US-20090209534-A1 | NOVEL COMPOUNDS AND USE OF TETRAHYDROPYRIDOPYRIDOTHIOPHENES | PEKARI KLAUS | 2009-08-20 | — | — | US | disclosed |
| EP-1866306-B1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2009-06-17 | — | — | EP | disclosed |
| US-6121274-A | PHOSPHODIESTERASE INHIBITOR FOR TREATMENT OF RESPIRATORY SYSTEM DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-09-19 | — | — | US | disclosed |
| WO-2000042020-A1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-07-20 | — | — | WO | disclosed |
| US-6080782-A | Cyclohexyl dihydrobenzofuranes | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-06-27 | — | — | US | disclosed |
| US-6011037-A | Thiazole derivatives with phosphodiesterase-inhibiting action | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-01-04 | — | — | US | disclosed |
| EP-0923568-A1 | NOVEL BENZOFURAN-4-CARBOXAMIDES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1999-06-23 | — | — | EP | disclosed |
| US-5902824-A | BRONCHIAL THERAPEUTICS, FOR ELIMINATION OF ERECTILE DYSFUNCTION AND FOR TREATMENT OF DISORDERS, PARTICULARLY THOSE OF INFLAMMATORY NATURE | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-05-11 | — | — | US | disclosed |
| WO-1998007715-A9 | NOVEL BENZOFURAN-4-CARBOXAMIDES | BYK GULDEN LOMBERG CHEM FAB (DE) | 1999-04-29 | — | — | WO | disclosed |
| WO-1998007715-A1 | NOVEL BENZOFURAN-4-CARBOXAMIDES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-02-26 | — | — | WO | disclosed |
| US-5712298-A | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-01-27 | — | — | US | disclosed |
| US-5599966-A | SUITABLE FOR TREATMENT OF DISEASES OF RESPIRATORY PASSAGES | BYK NEDERLAND BV (NL) | 1997-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NOS2, NOS1, ARG1 | PDE4D 336/4885PDE4A 87/4885PDE4B 189/4885 |
| US-11045456-B2 | Compositions and methods for treating COPD and other inflammatory conditions | PDE4B, PDE4A, PDE12 | PDE4D 8/4885PDE4A 2/4885PDE4B 1/4885 |
| US-20180042904-A1 | COMPOSITIONS AND METHODS FOR TREATING COPD AND OTHER INFLAMMATORY CONDITIONS | PDE4B, PDE4A, PDE12 | PDE4D 8/4885PDE4A 2/4885PDE4B 1/4885 |
| US-20090209534-A1 | NOVEL COMPOUNDS AND USE OF TETRAHYDROPYRIDOPYRIDOTHIOPHENES | RB1, MCL1, CCAR2 | PDE4D 3640/4885PDE4A 2732/4885PDE4B 3066/4885 |
| US-20090274676-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A PDE-4 INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | HSD11B2, PDE12, HSD3B1 | PDE4D 23/4885PDE4A 4/4885PDE4B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.